Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited announced the quotation of 450,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 30, 2025. This move indicates the company’s ongoing efforts to enhance its financial standing and operational capabilities, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$32.75 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments that address significant unmet needs in the medical field.
YTD Price Performance: 13.60%
Average Trading Volume: 734,102
Technical Sentiment Signal: Buy
Current Market Cap: A$1.79B
See more data about NEU stock on TipRanks’ Stock Analysis page.